Drugs harnessing cholinesterase inhibitors - which treat cognitive symptoms found in patients - have been found to reduce wandering, aggression and paranoia in Alzheimer's sufferers.
Publishing their findings in the Clinical Interventions in Aging journal, scientists at the Indiana University School of Medicine found that administering similar amounts to those with Alzheimer's lowered the problems and also showed no side effects.
Clinical pharmacy specialist Noll Campbell said the American Food and Drug Association had approved the medication, meaning that it could be increasingly introduced to the market and, in turn, bring benefits to the elderly.
He said that clinical trials of cholinesterase inhibitors could address "cognitive function as well as behavioural symptoms associated with dementia, and may improve the management of behavioural problems while reducing the use of more harmful medications that are needed to control behaviours".
There are currently four drugs used to treat Alzheimer's in the UK, with Aricept, Exelon and Reminyl being established inhibitors.
Exiba is the newest drug available, working in a different way from its counterparts.
Please click here for advice to help you find the right type of care.